Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 69
- Registration Number
- NCT02721641
Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 592
- Registration Number
- NCT02721004
A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 175
- Registration Number
- NCT02720120
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 99
- Registration Number
- NCT02717754
A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 334
- Registration Number
- NCT02716792
Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT02716779
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 243
- Registration Number
- NCT02715531
- Locations
- 🇺🇸
Stanford Cancer Institute; Hematology, Palo Alto, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT02711423
- Locations
- 🇺🇸
Bioclinica Research, Orlando, Florida, United States
Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)
Completed
- Conditions
- Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT02708732
- Locations
- 🇬🇧
PH Associates - an OPen Health Company, Marlow, United Kingdom
A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
Phase 2
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT02707640
© Copyright 2025. All Rights Reserved by MedPath